• Medical Information
  • Full Prescribing Information
  • Patient Site
  • Sign up for updates
QULIPTA Logo
  • QULIPTA Logo
  • Efficacy
    • 12-week Study
    • Patient Response
  • Safety
  • LTS Study
  • MOA
  • Dosing
  • Savings & Support
    • QULIPTA® Complete
    • Downloadable Resources
  • Sign up for updates

SIGN UP TO RECEIVE INFORMATION ABOUT QULIPTA™

Enter your details below
to receive the latest
information and other
educational resources.

request samples
Patient Savings
Request a rep

SIGN UP TO RECEIVE INFORMATION ABOUT QULIPTA™

Enter your details below
to receive the latest
information and other
educational resources.

request samples
Savings Enrollment
Request a rep

INDICATION

QULIPTA® (atogepant) is indicated for the preventive treatment of episodic migraine in adults.

IMPORTANT SAFETY INFORMATION

ADVERSE REACTIONS

The most common adverse reactions (at least 4% and greater than placebo) are nausea, constipation, and fatigue.

DRUG INTERACTIONS

Strong CYP3A4 Inhibitors: 10 mg once daily. 
Strong and Moderate CYP3A4 Inducers: 30 mg or 60 mg once daily. 
OATP Inhibitors: 10 mg or 30 mg once daily.

USE IN SPECIFIC POPULATIONS

Severe Renal Impairment or End-Stage Renal Disease: 10 mg once daily.
Avoid use in patients with severe hepatic impairment.

US-QLP-220116

IMPORTANT SAFETY INFORMATION

ADVERSE REACTIONS

The most common adverse reactions (≥5% and at least twice the rate of placebo) are nausea and constipation.

Please see full Prescribing Information.

Please see full Prescribing Information.

References

References: 1. QULIPTA (atogepant). Package insert. Allergan USA, Inc; 2021. 2. Ailani J, Lipton RB, Goadsby PJ, et al; ADVANCE Study Group. Atogepant for the preventive treatment of migraine. N Engl J Med. 2021;385(8):695-706. doi: 10.1056/NEJMoa2035908. 3. Data on file. Allergan USA, Inc. 4. Protocol for: Ailani J, Lipton RB, Goadsby PJ, et al; ADVANCE Study Group. Atogepant for the preventive treatment of migraine. N Engl J Med. 2021;385(8):695-706. doi: 10.1056/NEJMoa2035908. 5. Russo AF. Calcitonin gene-related peptide (CGRP): a new target for migraine. Annu Rev Pharmacol Toxicol. 2015;55:533-552. 6. Edvinsson L, Haanes KA, Warfvinge K, Krause DN. CGRP as the target of new migraine therapies—successful translation from bench to clinic. Nat Rev Neurol. 2018 Jun;14(6):338-350. doi:10.1038/s41582-018-0003-1 7. Edvinsson L. The trigeminovascular pathway: role of CGRP and CGRP receptors in migraine. Headache. 2017;57(suppl 2):47-55. doi:10.1111/head.13081

  • Follow us @
  • Facebook
  • Instagram
  • Twitter
  • Patient Site
  • Privacy Statement
  • Terms of Use
  • Advertising Choices
  • Cookies Settings
  • Important Safety Information
  • Full Prescribing Information
  • Contact Medical Information
  • Contact Us
  • Patient Site
  • Privacy Statement
  • Terms of Use
  • Advertising Choices
  • Cookies Settings

AbbVie Logo

© 2023 AbbVie. All rights reserved. QULIPTA® and its design are registered trademarks of Allergan Pharmaceuticals International Limited, an AbbVie company.

US-QULI-220006

Study Design

Two randomized, double-blind, placebo-controlled, parallel-group studies that evaluated the efficacy and safety of QULIPTA for 12 weeks in patients who were experiencing 4 to 14 migraine days per month. Patients in trials were 88% female, 80% White, 17% Black, and 12% Hispanic or Latino ethnicity and the mean age at study was 41 years (range 18-74 years).1

STUDY DESIGN

Two randomized, double-blind, placebo-controlled, parallel-group studies that evaluated the efficacy and safety of QULIPTA for 12 weeks in patients who were experiencing 4 to 14 migraine days per month. Patients in trials were 88% female, 80% White, 17% Black, and 12% Hispanic or Latino ethnicity and the mean age at study entry was 41 years (range 18-74 years).1,2

Phase 2b/3 Dose-finding Study Results:

QULIPTA 60 mg: -3.6 mothly migraine days across 12 weeks (n=177) (P=0.039).
QULIPTA 30 mg: -3.8 mothly migraine days across 12 weeks (n=182) (P=0.039).
QULIPTA 10 mg: -4.0 mothly migraine days across 12 weeks (n=92) (P=0.024). Placebo: -2.8 mothly migraine days across 12 weeks (n=178).1

INDICATION AND IMPORTANT SAFETY INFORMATION

QULIPTA® (atogepant) is indicated for the preventive treatment of episodic migraine in adults.

ADVERSE REACTIONS

The most common adverse reactions (at least 4% and greater than placebo) are nausea, constipation, and fatigue.

INDICATION AND IMPORTANT SAFETY INFORMATION

QULIPTA® (atogepant) is indicated for the preventive treatment of episodic migraine in adults.

ADVERSE REACTIONS

The most common adverse reactions (at least 4% and greater than placebo) are nausea, constipation, and fatigue.

INDICATION AND IMPORTANT SAFETY INFORMATION

QULIPTA® (atogepant) is indicated for the preventive treatment of episodic migraine in adults.

ADVERSE REACTIONS

The most common adverse reactions (at least 4% and greater than placebo) are nausea, constipation, and fatigue.

INDICATION AND IMPORTANT SAFETY INFORMATION

QULIPTA® (atogepant) is indicated for the preventive treatment of episodic migraine in adults.

ADVERSE REACTIONS

The most common adverse reactions (at least 4% and greater than placebo) are nausea, constipation, and fatigue.

INDICATION

QULIPTA® (atogepant) is indicated for the preventive treatment of episodic migraine in adults.

IMPORTANT SAFETY INFORMATION

ADVERSE REACTIONS

The most common adverse reactions (at least 4% and greater than placebo) are nausea, constipation, and fatigue.

DRUG INTERACTIONS

Strong CYP3A4 Inhibitors: 10 mg once daily. 
Strong and Moderate CYP3A4 Inducers: 30 mg or 60 mg once daily. 
OATP Inhibitors: 10 mg or 30 mg once daily.

USE IN SPECIFIC POPULATIONS

Severe Renal Impairment or End-Stage Renal Disease: 10 mg once daily.
Avoid use in patients with severe hepatic impairment.

US-QLP-220116

IMPORTANT SAFETY INFORMATION

ADVERSE REACTIONS

The most common adverse reactions (≥5% and at least twice the rate of placebo) are nausea and constipation.

Please see full Prescribing Information.